<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862990</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0414</org_study_id>
    <nct_id>NCT02862990</nct_id>
  </id_info>
  <brief_title>Evaluation of the Attitude of Pre Menopausal Women With Breast Cancer Faced With the Risk of Fertility Loss Caused by Chemotherapy</brief_title>
  <official_title>Evaluation of the Attitude of Pre Menopausal Women With Breast Cancer Faced With the Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo de Estudios Clínicos Oncológicos Peruano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the attitude of pre menopausal women with breast cancer faced with the risk of
      loss of fertility caused by chemotherapy using EORTC's Fertility Questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To characterize the attitude of pre menopausal patients with breast cancer regarding the
      risks of infertility based on the following variables:

        -  Age at diagnosis

        -  Number of children

        -  Will of having children

        -  Marital status

        -  Scholarity

        -  Period of time from the diagnosis

        -  Time of the last menstruation period

        -  Chemotherapy administration

        -  Clinical staging at the diagnosis

        -  Pathological evaluation

        -  Documentation of the cancer therapy
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To analyze the number of pre-menopausal patients diagnosed with breast cancer that did not agree in receiving chemotherapy due to the risk of infertility</measure>
    <time_frame>Baseline and 1 year after after the first interview</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infertility risk for breast cancer patients after accepting chemotherapy</measure>
    <time_frame>Baseline and 1 year after the first interview</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal percentage of cure necessary for patients accept the chemotherapy treatment</measure>
    <time_frame>Baseline and 1 year after the first interview</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age when diagnosed</measure>
    <time_frame>Baseline and 1 year after the first interview</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children</measure>
    <time_frame>Baseline and 1 year after the first interview</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desire to have kids</measure>
    <time_frame>Baseline and 1 year after the first interview</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marital status</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scholarity</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period of time since the diagnosis</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy scheme administration</measure>
    <time_frame>Baseline and 1 year after the first interview</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period of time from the last menstruation period</measure>
    <time_frame>Baseline and 1 year after the first interview</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of quality of life of patients with the EORTC QLQ-BR23</measure>
    <time_frame>Baseline and 1 year after the first interview</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Fertility</condition>
  <arm_group>
    <arm_group_label>Pre menopausal women with breast cancer</arm_group_label>
    <description>Pre menopausal women with breast cancer prior treatment in face of infertility evoked by chemotherapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pre menopausal women diagnosed with breast cancer prior treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with age ≥ 18 and ≤ 40

          -  Indication of (neo) adjuvant chemotherapy

          -  Prior chemotherapy treatment

          -  Patients with menstrual periods in the last 6 months

          -  In use of contraceptive methods

          -  Without breast cancer recurrence

          -  Capacity to read and understand the informed consent

        Exclusion Criteria:

          -  Patients which received or with indication of definitive ovarian suppression (surgery
             and/or radiotherapy), except temporary pharmacological ovarian suppression

          -  Patients whom initiated chemotherapy treatment before entering the study

          -  Altered state of mind, dementia, or any other psychiatry problem that can interfere in
             the comprehension or interpretation of the informed consent.

          -  Previous diagnosis of infertility
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Werutsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Latin American Cooperative Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Voelcker</last_name>
    <phone>55 51 3384 5334</phone>
    <email>laura.voelcker@lacog.org.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raíra Maschmann</last_name>
    <phone>55 51 3384 5334</phone>
    <email>raira.maschmann@lacog.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CPO - Pucrs</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Barrios, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCPA</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Liedke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pérola Byington</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>André Mattar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Oncologia y Radiobiologia</name>
      <address>
        <city>Havana</city>
        <country>Cuba</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cenro Oncologico Estatal ISSEMYM</name>
      <address>
        <city>Toluca de Lerdo</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>INEN</name>
      <address>
        <city>Surquillo</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Gomez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas San Agustín</name>
      <address>
        <city>Puerto Cabello</city>
        <country>Venezuela</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Contreras, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Cuba</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Venezuela</country>
  </location_countries>
  <link>
    <url>http://globocan.iarc.fr/Default.aspx</url>
    <description>Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010</description>
  </link>
  <reference>
    <citation>Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.</citation>
    <PMID>20610543</PMID>
  </reference>
  <reference>
    <citation>Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet. 2009 Apr 25;373(9673):1463-79. doi: 10.1016/S0140-6736(09)60316-0. Review.</citation>
    <PMID>19394537</PMID>
  </reference>
  <reference>
    <citation>Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, Gentilini O, Peccatori F, Fourquet A, Delaloge S, Marotti L, Penault-Llorca F, Kotti-Kitromilidou AM, Rodger A, Harbeck N; European Society of Breast Cancer Specialists. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012 Dec;48(18):3355-77. doi: 10.1016/j.ejca.2012.10.004. Epub 2012 Oct 29.</citation>
    <PMID>23116682</PMID>
  </reference>
  <reference>
    <citation>Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, Catalano G, Galimberti V, Nolé F, Martinelli G, Goldhirsch A. Very young women (&lt;35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002 Feb;13(2):273-9.</citation>
    <PMID>11886005</PMID>
  </reference>
  <reference>
    <citation>Vallejos Sologuren C, Gómez HL, et al. Clinicopathologic and outcome variables of worse prognosis in premenopausal patients (pts) age 35 and younger. 2010 Breast Cancer Symposium. Abstract 65</citation>
  </reference>
  <reference>
    <citation>Reichman BS, Green KB. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst Monogr. 1994;(16):125-9. Review.</citation>
    <PMID>7999454</PMID>
  </reference>
  <reference>
    <citation>Senkus E, Gomez H, Dirix L, Jerusalem G, Murray E, Van Tienhoven G, Westenberg AH, Bottomley A, Rapion J, Bogaerts J, Di Leo A, Nešković-Konstantinović Z. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psychooncology. 2014 Feb;23(2):173-82. doi: 10.1002/pon.3384. Epub 2013 Aug 29.</citation>
    <PMID>24038775</PMID>
  </reference>
  <reference>
    <citation>Gradishar WJ, Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 1989 Oct;16(5):425-36. Review.</citation>
    <PMID>2678491</PMID>
  </reference>
  <reference>
    <citation>Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer. 2006 Nov;6(11):886-93. Epub 2006 Oct 12. Review.</citation>
    <PMID>17036039</PMID>
  </reference>
  <reference>
    <citation>Dnistrian AM, Schwartz MK, Fracchia AA, Kaufman RJ, Hakes TB, Currie VE. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer. 1983 Mar 1;51(5):803-7.</citation>
    <PMID>6687378</PMID>
  </reference>
  <reference>
    <citation>Moore HCF, et al. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in earlystage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J Clin Oncol 32:5s, 2014 (suppl; abstr LBA505)</citation>
  </reference>
  <reference>
    <citation>Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, Kaasa S, Nilsson J, Wiklund T, Wilking N, Bergh J; Scandinavian Breast Group Study 9401. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol. 2003 Oct 1;21(19):3659-64.</citation>
    <PMID>14512398</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Fertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

